Show simple item record

dc.contributor.authorOwino, F
dc.contributor.authorMandala, J
dc.contributor.authorAmbia, J
dc.contributor.authorAgot, v
dc.contributor.authorVan Damme, L
dc.date.accessioned2014-03-05T06:40:44Z
dc.date.available2014-03-05T06:40:44Z
dc.date.issued2013-11
dc.identifier.citationInt Med Case Rep J. 2013 Nov 29;6:91-3. doi: 10.2147/IMCRJ.S52015. eCollection 2013.en_US
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/pubmed/24353443
dc.identifier.urihttp://hdl.handle.net/11295/65069
dc.description.abstractSide effects of antiretroviral drug use by HIV-positive patients have been extensively studied; however, there are limited data on the side effects of antiretroviral drugs used as an HIV prophylaxis among healthy, HIV-negative individuals. Here we report on an unusual neuropathy in a 24-year-old participant in the FEM-PrEP trial. This was a Phase III randomized, double blind, placebo-controlled trial to test the safety and effectiveness of tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) (TDF-FTC) to prevent HIV. At the eighth week of taking TDF-FTC with moderate adherence, the participant complained of mild paresthesiae, numbness, and a tingling sensation in her upper limbs that was associated with pain and cold. After an additional 4 days, she developed a disabling weakness of her upper limbs and tremors in her hands. The study product was discontinued, and within 2 weeks she was free of all symptoms. One month after restarting the drug, she complained of posture-dependent numbness of her upper limbs. Results of clinical and neurological exams, laboratory tests, and magnetic resonance imaging are described here.en_US
dc.language.isoenen_US
dc.publisherUniversity of Nairobien_US
dc.titleNeurological syndrome in an HIV-prevention trial participant randomized to daily tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) in Bondo, Kenyaen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record